CHU La Timone


Bâtiment 3

264 Rue Saint-Pierre  
13385 Marseille Cedex 5


Mail :



Direction :

Pr Olivier BLIN

Directeur du Centre de Pharmacologie Clinique et d'évaluations thérapeutiques 


Chef de projet :

Dr Georges KHALIL


Business developer

Dr Joanie DEL BANO




DHUNE, Centre d’excellence pour les Maladies Neurodégénératives et le Vieillissement
DHUNE, Centre d’excellence pour les Maladies Neurodégénératives et le Vieillissement

Industrial and Pharmaceutical Partners

VECT-HORUS is a highly innovative biotechnology company that designs and develops peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs, notably into the brain, and to tumors. Combining drugs or imaging agents to its vectors allows them to cross biological barriers, notably the blood-brain barrier (BBB).http://www.vect-horus.com/


Horus Pharma develops, patents and markets products in the ophthalmological and dermatological fields. Focused on patient safety, our laboratory has developed a recognized expertise in the development of reservative-free formulations and product delivery systems. With several patents to its credit, Horus Pharma pursues a voluntary policy of innovation, to follow its R&D guiding principle:                                                      meet patient expectations and respond to healthcare professionals’                                                    concerns with innovative and practical solutions. The launch in 2015                                                    of our first European subsidiaries marks an important milestone in                                                      Horus Pharma Group's international expansion strategy.                                                                    www.horus-pharma.com

InFlectis BioScience is a private drug discovery company aiming at targeting and modulating interaction between proteins involved in key human pathophysiological processes. The company develops small molecule drugs that specifically target the Unfolded Protein Response (UPR) in order to treat misfolding protein disorders such                                                      as neurodegenerative and age-related diseases.



Innovative Concepts in Drug Development (ICDD) is a biotech company dedicated to identifying molecular determinants of pre-dementia stages of neurodegenerative diseases. ICDD develops immunoanalyses using proprietary technologies based on pertinent proteins identified by cellulomic and proteomic approaches. http://www.icdd-sas.com/


Neuron Experts is a Contract Research Organization (CRO) specialized in the study of neuro-active compounds. The company uses its own tests based on primary neuronal cell cultures that are modeling neurodegenerative diseases and neuronal impairment-induced skin disorders.




Provepharm is a company focusing on the development and valorization of APIs and Drug Products worldwide. Its specialization lies in the development and commercialization of pharmaceutical drug products derived from active substances synthesized and patented by its parent company ProvenceTechnologies. http://www.provepharm.com/



Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY).                                                                          http://www.sanofi.com


Amylgen is a privately owned contract research organization (CRO) offering a unique combination of validated in vivo models and a behavioral, biochemical and morphological testing, allowing fast and predictive screening of the effects of drugs and nutraceuticals on brain health and CNS disorders like depression, schizophrenia, anxiety and neurodegenerative diseases (eg Alzheimer and Parkinson). http://www.amylgen.fr/

SigmaThera SAS is a newly created company as a spinoff from AMYLGEN. Its creation is aiming at the repurposing of SIT161 in neuroprotection. Already tested in various clinical trials, SIT161 has demonstrated excellent safety and is acting through sigma-1 receptors, which have been demonstrated to play an important role in neuroprotection.


Neuroservice is a private CRO providing pharmacological assays based on electrophysiological recordings (Multi-Electrode Array (MEA) and Patch-Clamp) of acute brain slices, spinal cord slices, human brain slices and cultured neurons. Neuroservice supports the early phases of CNS and PAIN R&D programs in Lead Selection & Optimization as well as in the investigation of Mechanism of Action for experimental compounds. http://www.neuroservice.com/

Epiona is dedicated to the management of scientific and pharmaceutical projects, primarily focusing on psychiatric disorders and neurodegeneration. It is our goal to help laboratories and companies to accelerate the transfer of their knowledge from basic research towards practical applications. Thanks to technologies such as Crispr/Cas9 or the injection of viral vectors (AAV / CAV), we can develop reliable pathology models. In our laboratories we are testing molecules from proof of concept to efficacy testing, while also focusing on pharmacokinetics.

Qualissima is a Research as a Service Company (RaaS), founded in 2001. We offer to our partners (health products industries and public research), 3 platforms: Clinical research (CRO and SMO), scientific & regulatory consulting and online surveys (Web portal). We propose proof of concept studies, proof of activities studies, medical devices studies and observational studies.

Our main area skills: neurodegeneration, CNS                                                                                    http://www.qualissima.com/



Syncrosome offer relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds. We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored in vivo experimental protocols to give you appropriate answers. Our main activities consit in :

In vitro Drug Efficacy Studies for Central Nervous System with models in Parkinson, Alzheimer and Stroke disease ; In vivo Drug Efficacy Studies for: Central Nervous System, Cardiovascular and Metabolic disease,  Respiratory, Gastroenterology ; CNS-PK with a special focus in the study of the Blood Brain Barrier passage and/or Neurotransmitter monitoring ; Early bioavailibity studies (PK/PD) on rodents and non-rodents. https://www.syncrosome.com